Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Are the Latest Market Insights for the Postherpetic Neuralgia (PHN) Industry?

The market size for postherpetic neuralgia (phn) has significantly expanded in the past few years. It is expected to increase from a value of $0.72 billion in 2024 to $0.77 billion in 2025, marking a compound annual growth rate (CAGR) of 7.0%. This growth during the historical period can be credited to factors such as the rising number of herpes zoster infection cases, an aging population, heightened awareness among both patients and healthcare professionals, a growing demand for efficient solutions to manage neuropathic pain, and an increase in healthcare spending.

The market for postherpetic neuralgia (phn) is projected to experience substantial expansion in the forthcoming years, rising to $0.99 billion by 2029 with a compound annual growth rate (CAGR) of 6.6%. This growth during the forecast period could be due to the increased utilization of antiviral medications and vaccines, a growing incidence of chronic pain disorders, rising implementation of sophisticated drug delivery systems, an increase in clinical trials and investment in research and development, and a surge in regulatory approvals for innovative therapeutics. Looking forward, the market trends will be driven by progress in neuropathic pain research, evolution in drug delivery technologies, advances in technology-enabled diagnostic aids, the application of artificial intelligence in clinical trials, and progress in non-opioid pain control alternatives.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24664&type=smp

What Forces Are Driving The Growth Of The Postherpetic Neuralgia (PHN) Industry?

The anticipated surge in the postherpetic neuralgia (PHN) market is primarily ascribed to the growing incidence of chronic pain conditions. Chronic pain, which typically lasts longer than three months, tends to be persistent or recurrent, often surpassing the average course of a disease or injury and compromising an individual’s daily activities and overall quality of life. The increased emergence of chronic pain conditions is a consequence of an aging population, as elderly individuals are more susceptible to degenerative diseases such as arthritis and neuropathy, ultimately resulting in persistent pain. Postherpetic neuralgia contributes significantly to chronic pain research, providing an explicit model to explore mechanisms behind nerve-related pain and evaluate enduring treatment tactics. For instance, in January 2024, a report issued by the Office for Health Improvement and Disparities, a governmental department based in UK, disclosed that approximately 18.4% of people aged 16 and above reported suffering from a long-term musculoskeletal (MSK) condition in 2023, presenting an increase from 17.6% the previous year. Consequently, the escalating rates of chronic pain conditions are bolstering the progress of the postherpetic neuralgia (PHN) market.

What Is The Overview Of Market Segmentation In The Postherpetic Neuralgia (PHN) Industry?

The postherpetic neuralgia (PHN) market covered in this report is segmented –

1) By Type: Patches, Drugs, Opioids

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

3) By End Users: Hospitals, Clinics, Ambulatory Surgical Centers, Other End Users

Subsegments:

1) By Patches: Transdermal Drug Delivery Patches, Nicotine Patches, Hormone Replacement Therapy Patches, Analgesic Patches, Orthopedic Support Patches

2) By Drugs: Prescription Drugs, Over-The-Counter (OTC) Drugs, Generic Drugs, Branded Drugs, Biologic Drugs

3) By Opioids: Natural Opioids, Semi-Synthetic Opioids, Synthetic Opioids, Opioid Analgesics, Opioid Antagonists

What Future Market Trends Are Projected For The Postherpetic Neuralgia (PHN) Industry?

Primary businesses in the postherpetic neuralgia (PHN) sector are working diligently to secure regulatory clearances. These approvals help diversify their product range, give them a competitive edge, and address the substantial unmet healthcare requirement for more effective and bearable treatments. These clearances are the official consents provided by government health bodies that authorize the legal marketing and utilization of a medication or remedy for a specific health issue. To illustrate, Zydus Lifesciences Ltd., a pharmaceutical firm based in India, secured the final approval from the United States Food and Drug Administration in February 2023. This permitted the company to produce and sell once-per-day generic Gabapentin Tablets, available in 300 mg and 600 mg doses, for the treatment of postherpetic neuralgia (PHN). These Gabapentin tablets are designed to manage PHN, a type of neuropathic discomfort caused by nerve damage following the reactivation of the varicella-zoster virus. For PHN, the recommended dosage begins at 300 mg on day one, goes up to 600 mg (twice a day at 300 mg) on the second day, and reaches 900 mg (three times a day at 300 mg) on the third day. The dosage can be increased up to 1800 mg daily (600 mg three times a day) as required for alleviating pain.

Who Are The Primary Players Operating Across The Global Postherpetic Neuralgia (PHN) Market?

Major companies operating in the postherpetic neuralgia (PHN) market are Pfizer Inc., Merck & Co. Inc., Novartis AG, GlaxoSmithKline plc, Teva Pharmaceutical Industries Limited, Astellas Pharma Inc., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Limited, Mylan N.V., Mallinckrodt plc, Merz Therapeutics GmbH, Acorda Therapeutics Inc., Scilex Holding Company, Elorac Inc., Lexicon Pharmaceuticals Inc., Oxford Cannabinoid Technologies Holdings plc, Teikoku Pharma USA Inc., Acasti Pharma Inc., Flexion Therapeutics Inc., Haisco Pharmaceutical Group Co. Ltd., Shanghai SIMR Biotechnology Co. Ltd.

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/postherpetic-neuralgia-phn-global-market-report

Which Region Offers The Most Growth Potential For The Postherpetic Neuralgia (PHN) Market Through 2029?

North America was the largest region in the postherpetic neuralgia (PHN) market in 2024. The regions covered in the postherpetic neuralgia (PHN) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=24664&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model